Plain-English translation of NCT05285917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a well-established medication for sickle cell disease, in 400 children in Angola. The study will compare two different ways of starting the medication—using a weight-based dose versus an individualized dose based on how your child's body processes the drug. The goal is to figure out how to safely and effectively use this treatment in places where advanced laboratory testing may not be available.
is known to help reduce pain and complications from sickle cell disease, but it is not widely used in sub-Saharan Africa because doctors are unsure about the best dosing strategies and what level of laboratory monitoring is actually needed. This trial aims to create practical guidelines so that this medication can be made available to many more children across Africa.
You likely qualify if…
You likely don't qualify if…
Your child will be randomly assigned to receive the medication starting at either a weight-based dose or an individualized dose calculated using a special computer program. The study will carefully monitor your child's health and blood counts using a portable machine to measure medication levels, with visits and blood tests designed to keep laboratory requirements manageable. The researchers will track how well the medication works and how safe it is, with the goal of creating guidelines that other doctors across Africa can follow.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Angola